Latest updates for Fdnrx

Fresh curated links around FDNRX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Market Street Expands Its DFGX Holdings in $3.5 Million Buy
  • Franklin DynaTech Fund Q1 2026 Commentary
  • Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

fool.com /1 month ago

Market Street Expands Its DFGX Holdings in $3.5 Million Buy

This ETF provides diversified exposure to global ex-U.S. fixed income, spanning government, corporate, and supranational bonds.

Read source
seekingalpha.com /2 weeks ago

Franklin DynaTech Fund Q1 2026 Commentary

Read source
fool.com /1 week ago

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

Read source
seekingalpha.com /1 month ago

FGN And FGSN: F&G Annuities' 2 Long-Dated Notes - The Second Has A Buy Rating

Read source
fool.com /1 week ago

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.

Read source
fool.com /1 week ago

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.

Read source
fool.com /1 month ago

Is DFGX a Smart International Bond Play? One Wealth Manager Just Added $3.9 Million Worth

This ETF provides diversified access to non-US government and corporate bonds across global fixed income markets.

Read source
seekingalpha.com /2 weeks ago

Nomura Global Listed Real Assets Fund Q1 2026 Commentary

Read source
seekingalpha.com /1 week ago

NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript

Read source
seekingalpha.com /6 days ago

FDRR: Not The Best ETF For Rising Rates

Read source
seekingalpha.com /1 month ago

Definium Therapeutics, Inc. (DFTX) Analyst/Investor Day - Slideshow

Read source
seekingalpha.com /11 hours ago

FDL: Regular Dividends And Relative Value (Reaffirming Buy)

Read source
seekingalpha.com /1 month ago

flatexDEGIRO SE (FNNTF) Q1 2026 Earnings Call Transcript

Read source
seekingalpha.com /1 month ago

FDJ United (LFDJF) Shareholder/Analyst Call - Slideshow

Read source
seekingalpha.com /2 days ago

Baron Durable Advantage Fund adds LRCX; exits DHR and CSGP

Read source
seekingalpha.com /1 month ago

Triple-Factor Closed-End Fund Report: EFR Stands Out (March 2026)

Read source
seekingalpha.com /1 month ago

Diebold Nixdorf: Index Inclusion Is Additional Validation Of Diebold Nixdorf's Turnaround

Read source
fool.com /3 weeks ago

Francis Financial Doubles Down on Fixed Income With $7.8M FLXR Buy

The TCW Flexible Income ETF targets high current income through a flexible approach to fixed-income markets.

Read source
fool.com /1 week ago

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.

Read source
fool.com /1 week ago

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.

Read source
seekingalpha.com /4 days ago

Nomura Real Estate Securities Fund Q1 2026 Commentary

Read source
seekingalpha.com /3 weeks ago

Fidelity Select Consumer Staples Portfolio Q1 2026 Commentary

Read source
seekingalpha.com /11 hours ago

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

Read source
fool.com /1 month ago

$1,000 and the Right Dividend Stock: This Is the One to Buy Right Now

Among other wonderful traits, it boasts a hefty 5% dividend yield.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Fdnrx

seekingalpha.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

fool.com

Recent coverage from public sources
Public source